Platform Overview
The Ncardia iPSC Platform utilizes human iPSC to manufacture differentiated cells at scale and employ targeted assays to characterize and test from identity to functionality.
The Platform is employed in Drug Discovery and Cell Therapy. In both segments we start with human iPSC to manufacture the cell of interest. In Drug Discovery, we develop assays to compound effects compatible with high-throughput screening technologies. This includes target discovery & validation, primary or secondary screening, Hit-to-Lead optimization and pre-clinical development.
For Cell Therapy projects, the Platform is equally suited to yield the required functionality, potency and safety data. Each project is led by the appropriate scientific domain experts in cardiovascular, neuroscience and immunology, as well as process development and manufacturing scientists.